JP5252787B2 - Method for inhibiting degradation of thermally unstable drugs - Google Patents
Method for inhibiting degradation of thermally unstable drugs Download PDFInfo
- Publication number
- JP5252787B2 JP5252787B2 JP2006210644A JP2006210644A JP5252787B2 JP 5252787 B2 JP5252787 B2 JP 5252787B2 JP 2006210644 A JP2006210644 A JP 2006210644A JP 2006210644 A JP2006210644 A JP 2006210644A JP 5252787 B2 JP5252787 B2 JP 5252787B2
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic solution
- prost
- thermally unstable
- trometamol
- eye drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 12
- 230000015556 catabolic process Effects 0.000 title claims description 5
- 238000006731 degradation reaction Methods 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title description 22
- 239000003814 drug Substances 0.000 title description 22
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 239000002997 ophthalmic solution Substances 0.000 claims description 32
- 229940054534 ophthalmic solution Drugs 0.000 claims description 32
- 239000003889 eye drop Substances 0.000 claims description 18
- 238000000354 decomposition reaction Methods 0.000 claims description 14
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 13
- 229960000281 trometamol Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 229960001160 latanoprost Drugs 0.000 description 10
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 6
- 229960004458 tafluprost Drugs 0.000 description 6
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 6
- 229950008081 unoprostone isopropyl Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- -1 amine compound Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960004811 pemirolast potassium Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960002368 travoprost Drugs 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- UMYAMXGXQKNONL-UHFFFAOYSA-M C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].B(O)(O)O.[K+] Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].B(O)(O)O.[K+] UMYAMXGXQKNONL-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124342 antiallergic ophthalmic agent Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、熱的に不安定な薬物を含有する点眼液に有機アミンを配合することにより、点眼液中の熱的に不安定な薬物の分解を抑制する方法、および熱的に不安定な薬物を含有する点眼液に有機アミンを配合することにより、点眼液中の熱的に不安定な薬物の分解が抑制された点眼液組成物に関する。 The present invention relates to a method for inhibiting the decomposition of a thermally unstable drug in eye drops by blending an organic amine with an eye drop containing a thermally unstable drug, and a thermally unstable The present invention relates to an ophthalmic solution composition in which decomposition of a thermally unstable drug in an ophthalmic solution is suppressed by adding an organic amine to the ophthalmic solution containing the drug.
点眼液には、例えばラタノプロスト、イソプロピルウノプロストン、タフルプロスト、トラボプロスト等のプロスタグランジン誘導体、コハク酸メチルプレドニゾロンナトリウム、酢酸プレドニゾロン等のエステル化されたステロイド、パラオキシ安息香酸エチル、アミノ安息香酸エチル、プロカイン、アスピリン等のカルボン酸エステルなど熱に不安定な薬物を配合することがある。 Eye drops include, for example, prostaglandin derivatives such as latanoprost, isopropyl unoprostone, tafluprost, travoprost, esterified steroids such as methylprednisolone sodium succinate, prednisolone acetate, ethyl paraoxybenzoate, ethyl aminobenzoate, Sometimes heat-labile drugs such as carboxylic acid esters such as procaine and aspirin are added.
しかし、流通過程や貯蔵過程で、点眼液の保管温度が上昇することがあり、点眼液に熱的に不安定な薬物が含まれている場合には、保管温度が上昇して該薬物が分解すると所望の薬効が発揮されず、さらに、浮遊物が発生したり、点眼液が白濁することもある。冷所で保管すれば、熱に不安定な薬物の分解を効果的に抑制できるが、点眼液は様々な環境に晒されるので、冷所での保管以外の方法で該薬物の分解を抑制する必要がある。 However, the storage temperature of eye drops may increase during the distribution process or storage process. If the eye drops contain a thermally unstable drug, the storage temperature increases and the drug decomposes. As a result, the desired medicinal effect is not exhibited, and suspended matter may be generated, or the ophthalmic solution may become cloudy. If stored in a cool place, the decomposition of heat-labile drugs can be effectively suppressed, but the ophthalmic solution is exposed to various environments, so that the decomposition of the drug is suppressed by a method other than storage in a cold place. There is a need.
ところで、点眼液には、水溶性の有機アミンを緩衝剤として添加するのが一般的であるが、それ以外の目的で水溶性の有機アミンを配合することもある。 By the way, it is common to add a water-soluble organic amine as a buffering agent to the ophthalmic solution, but a water-soluble organic amine may be added for other purposes.
特許文献１は、抗アレルギー眼科用剤に関する発明を開示したものであり、ペミロラストカリウム（薬物）に有機アミンを配合することによって、ペミロラストカリウムの結晶析出を防止できることが記載されている。また、特許文献２は、テトラゾール誘導体を含有する点眼剤に関する発明を開示したものであり、塩基性アミン化合物を配合すればカチオン系防腐剤の防腐効果を増強できることが記載されている。 Patent Document 1 discloses an invention relating to an antiallergic ophthalmic agent, and describes that it is possible to prevent crystal precipitation of pemirolast potassium by blending an organic amine with pemirolast potassium (drug). . Patent Document 2 discloses an invention relating to an eye drop containing a tetrazole derivative, and describes that the antiseptic effect of a cationic preservative can be enhanced by adding a basic amine compound.
しかしながら、熱的に不安定な薬物を含有する点眼液に有機アミンを配合することによって、該薬物を安定化し、その分解を抑制する報告はない。
流通過程や貯蔵過程で点眼液の保管温度が上昇しても、点眼液に含まれる熱的に不安定な薬物の分解を抑制し、該点眼液を安定化することが望まれている。 Even when the storage temperature of the eye drop increases during the distribution process or the storage process, it is desired to suppress the decomposition of the thermally unstable drug contained in the eye drop and stabilize the eye drop.
本発明者らは、熱的に不安定な薬物の分解を抑制するために鋭意研究したところ、熱的に不安定な薬物を含有する点眼液に有機アミンを配合すれば、点眼液中の該薬物の分解を効果的に抑制でき、点眼液を安定に保存できることを見出した。 The present inventors have intensively studied to suppress the decomposition of a thermally unstable drug. When an organic amine is added to an ophthalmic solution containing a thermally unstable drug, the It was found that the decomposition of the drug can be effectively suppressed and the ophthalmic solution can be stored stably.
すなわち、本発明は、
（１）タフルプロストを含有する点眼液にトロメタモールを配合することにより、点眼液中のタフルプロストの分解を抑制する方法、
（２）タフルプロストを含有する点眼液にトロメタモールを配合し、かつ、ｐＨを４〜８の範囲とすることにより、点眼液中のタフルプロストの分解を抑制する方法、
（３）タフルプロストを含有する点眼液にトロメタモールを配合することにより、点眼液中のタフルプロストの分解が抑制された点眼液組成物、および
（４）タフルプロストを含有する点眼液にトロメタモールを配合し、かつ、ｐＨを４〜８の範囲とすることにより、点眼液中のタフルプロストの分解が抑制された点眼液組成物、である。
That is, the present invention
(1) By blending trometamol in an eye drop containing data full Prost, a method of suppressing the degradation of data full Prost in the ophthalmic solution,
(2) data blended trometamol in an eye drop containing full Prost, and by the range of 4-8 a pH, a method of suppressing the degradation of data full Prost in the ophthalmic solution,
(3) By adding trometamol in an eye drop containing data full Prost, ophthalmic solution composition decomposition is decreased in data full Prost in the ophthalmic solution, and (4) the eye drop containing the data full Prost blended trometamol, and by the range of 4-8 a pH, ophthalmic solution composition decomposition is decreased in data full Prost in the ophthalmic solution is.
本発明において、熱的に不安定な薬物は、常温（２５℃）よりも温度が高くなると点眼液中で分解する傾向のある薬物であり、例えば、ラタノプロスト、イソプロピルウノプロストン、タフルプロスト、トラボプロスト等のエステル結合を有する熱的に加水分解する傾向のあるプロスタグランジン誘導体である。
In the present invention, thermally unstable drug, Ri drug der which tend to decompose in ophthalmic solution temperature than the room temperature (25 ° C.) is higher, if example embodiment, latanoprost, isopropyl unoprostone, tafluprost, travoprost is a Ah pulp prostaglandin derivative of thermally hydrolyze tend to have an ester bond or the like.
点眼液中のイソプロピルウノプロストンまたはタフルプロストの濃度は、該イソプロピルウノプロストンまたはタフルプロストが所望の薬効を奏する濃度であれば特に制限されないが、例えば０．００００１〜１０％（Ｗ／Ｖ）である。
The concentration of isopropyl unoprostone or tafluprost in the ophthalmic solution is not particularly limited as long as the isopropyl unoprostone or tafluprost has a desired drug effect, and is, for example, 0.00001 to 10% (W / V). .
有機アミンは、好ましくはトロメタモールである。
Organic amines, good Mashiku is Torometamo Le.
点眼液中のトロメタモールの濃度は特に限定されないが、０．００１〜５％（Ｗ／Ｖ）が好ましく、より好ましくは０．００５〜３％（Ｗ／Ｖ）である。
The concentration of trometamol in the ophthalmic solution is not particularly limited, 0. 001 to 5% (W / V) is preferable, and 0.005 to 3% (W / V) is more preferable.
本発明の点眼液は汎用されている方法によって調製することができ、必要に応じて等張化剤、緩衝剤、ｐＨ調節剤、可溶化剤、増粘剤等を添加することができる。 The ophthalmic solution of the present invention can be prepared by a widely used method, and an isotonic agent, a buffer, a pH adjuster, a solubilizer, a thickener, etc. can be added as necessary.
等張化剤としては、例えばグリセリン、プロピレングリコール、ポリエチレングリコール、トリハロース、シュクロース、ソルビトール、マンニトール、塩化ナトリウム、塩化カリウム、塩化カルシウム、塩化マグネシウム等を挙げることができる。 Examples of the isotonizing agent include glycerin, propylene glycol, polyethylene glycol, trihalose, sucrose, sorbitol, mannitol, sodium chloride, potassium chloride, calcium chloride, magnesium chloride and the like.
緩衝剤としては、例えばリン酸ナトリウム、リン酸二水素ナトリウム、リン酸水素二ナトリウム、リン酸カリウム、リン酸二水素カリウム、リン酸水素二カリウム等のリン酸塩；ホウ酸ナトリウム、ホウ酸カリウム等のホウ酸塩；クエン酸ナトリウム、クエン酸二ナトリウム等のクエン酸塩；酢酸ナトリウム、酢酸カリウム等の酢酸塩、炭酸ナトリウム、炭酸水素ナトリウム等の炭酸塩等を挙げることができる。 Examples of the buffer include phosphates such as sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate; sodium borate, potassium borate Citrates such as sodium citrate and disodium citrate; acetates such as sodium acetate and potassium acetate; carbonates such as sodium carbonate and sodium hydrogencarbonate;
ｐＨ調節剤としては、例えば塩酸、クエン酸、リン酸、酢酸、水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウム等を挙げることができる。 Examples of the pH regulator include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like.
可溶化剤としては、例えばポリソルベート８０、ポリエキシエチレン硬化ヒマシ油６０、マクロゴール４０００等を挙げることができる。 Examples of the solubilizer include polysorbate 80, polyethylene ethylene hardened castor oil 60, macrogol 4000, and the like.
増粘剤としては、例えばヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルアルコール、カルボキシビニルポリマー、ポリビニルピロリドン等を挙げることができる。 Examples of the thickener include hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, carboxyvinyl polymer, polyvinylpyrrolidone and the like.
本発明の点眼液のｐＨは３〜９、特に４〜８とするのが好ましい。 The pH of the ophthalmic solution of the present invention is preferably 3 to 9, particularly 4 to 8.
イソプロピルウノプロストンまたはタフルプロストを含有する点眼液にトロメタモールを配合すれば、点眼液中のイソプロピルウノプロストンまたはタフルプロストの分解を効果的に抑制できるので、安定な点眼液を提供することができる。
If blended trometamol in an eye drop containing isopropyl unoprostone or tafluprost, since it effectively suppress the decomposition of isopropyl unoprostone or tafluprost in ophthalmic solution, it is possible to provide a stable ophthalmic solution.
［熱安定性試験］
熱的に不安定な薬物として、ラタノプロスト（化学名：イソプロピル−（Ｚ）−７［（１Ｒ，２Ｒ，３Ｒ，５Ｓ）３，５−ジヒドロキシ−２−［（３Ｒ）−３−ヒドロキシ−５−フェニルペンチル］シクロペンチル］−５−ヘプタノエート）を用いて、熱安定性試験を行った。
[Thermal stability test]
As a thermally unstable drug, latanoprost (chemical name: isopropyl- (Z) -7 [(1R, 2R, 3R, 5S) 3,5-dihydroxy-2-[(3R) -3-hydroxy-5- Phenylpentyl] cyclopentyl] -5-heptanoate) was used to conduct a thermal stability test.
（１）試料調製
処方１
トロメタモール１ｇを精製水約８０ｍＬに溶解し、希塩酸でｐＨを７．０に調整し、精製水で全量１００ｍＬとし、基剤とした。ラタノプロスト５ｍｇに基剤１００ｍＬを加え、約８０℃の水浴中で加温しながら撹拌し、ラタノプロストを溶解させた。これを室温に戻した後ｐＨが７．０であることを確認した。
(1) Sample preparation formula 1
1 g of trometamol was dissolved in about 80 mL of purified water, the pH was adjusted to 7.0 with dilute hydrochloric acid, and the total volume was made up to 100 mL with purified water, which was used as a base. 100 mL of the base was added to 5 mg of latanoprost, and the mixture was stirred while warming in a water bath at about 80 ° C. to dissolve latanoprost. After returning this to room temperature, it was confirmed that the pH was 7.0.
比較処方１
リン酸二水素ナトリウム（緩衝剤）１ｇを精製水約８０ｍＬに溶解し、１Ｎ水酸化ナトリウムでｐＨを７．０に調整し、精製水で全量１００ｍＬとし、基剤とした。ラタノプロスト５ｍｇに基剤１００ｍＬを加え、約８０℃の水浴中で加温しながら撹拌し、ラタノプロストを溶解させた。これを室温に戻した後ｐＨが７．０であることを確認した。
Comparative prescription 1
1 g of sodium dihydrogen phosphate (buffering agent) was dissolved in about 80 mL of purified water, the pH was adjusted to 7.0 with 1N sodium hydroxide, and the total volume was made up to 100 mL with purified water. 100 mL of the base was added to 5 mg of latanoprost, and the mixture was stirred while warming in a water bath at about 80 ° C. to dissolve latanoprost. After returning this to room temperature, it was confirmed that the pH was 7.0.
（２）試験方法及び結果
処方１および比較処方１を５ｍLずつガラスアンプルに充填し、それぞれについて８０℃で４週間および５０℃で８週間保存した後、ラタノプロストの含有量を高速液体クロマトグラフィー（ＨＰＬＣ）を用いて定量し、残存率を求めた。試験結果を表１に示す。
（３）考察
表１から明らかなように、トロメタモールを配合した点眼液（試料１）のラタノプロストの残存率は、リン酸二水素ナトリウムを配合した点眼液（比較試料１）の残存率よりも大きい。したがって、熱的に不安定な薬物（ラタノプロスト）を含有する点眼液に有機アミン（トロメタモール）を配合すれば、点眼液中の熱的に不安定な薬物の分解を効果的に抑制し、安定に保存できる。
(3) Discussion As is apparent from Table 1, the residual rate of latanoprost in the ophthalmic solution containing trometamol (sample 1) is larger than the residual rate of the ophthalmic solution containing sodium dihydrogen phosphate (comparative sample 1). . Therefore, when an organic amine (trometamol) is added to an ophthalmic solution containing a thermally unstable drug (latanoprost), the decomposition of the thermally unstable drug in the ophthalmic solution is effectively suppressed and stabilized. Can be saved.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006210644A JP5252787B2 (en) | 2005-08-02 | 2006-08-02 | Method for inhibiting degradation of thermally unstable drugs |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005223862 | 2005-08-02 | ||
| JP2005223862 | 2005-08-02 | ||
| JP2006210644A JP5252787B2 (en) | 2005-08-02 | 2006-08-02 | Method for inhibiting degradation of thermally unstable drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010289627A Division JP2011057717A (en) | 2005-08-02 | 2010-12-27 | Method for preventing degradation of isopropylunoprostone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007063265A JP2007063265A (en) | 2007-03-15 |
| JP5252787B2 true JP5252787B2 (en) | 2013-07-31 |
Family
ID=37925850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006210644A Active JP5252787B2 (en) | 2005-08-02 | 2006-08-02 | Method for inhibiting degradation of thermally unstable drugs |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5252787B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123278B1 (en) | 2007-02-07 | 2013-01-09 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
| KR101600111B1 (en) * | 2008-04-23 | 2016-03-04 | 오쓰까 세이야꾸 가부시키가이샤 | Eye-drop preparation and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4305947A (en) * | 1980-08-26 | 1981-12-15 | Survival Technology, Inc. | Stable aqueous solutions of pralidoxime salts |
| JP2849922B2 (en) * | 1989-05-26 | 1999-01-27 | 吉富製薬株式会社 | Liquid composition containing plasminogen activator |
| JP3170619B2 (en) * | 1995-04-20 | 2001-05-28 | 参天製薬株式会社 | Planoprofen ophthalmic solution containing organic amine |
| AR002194A1 (en) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT. |
| CN1146423C (en) * | 1998-07-14 | 2004-04-21 | 阿尔康实验室公司 | Prostaglandin product |
| JP2003146881A (en) * | 2001-11-14 | 2003-05-21 | Toyo Pharmar Kk | Anti-allergic ophthalmic preparation |
| ATE357219T1 (en) * | 2002-01-25 | 2007-04-15 | Glaxo Group Ltd | DOSAGE FORMS FOR DNA |
| JP4314429B2 (en) * | 2002-08-23 | 2009-08-19 | 参天製薬株式会社 | Stable ophthalmic solution containing latanoprost as an active ingredient |
| BRPI0414149A (en) * | 2003-09-05 | 2006-10-31 | Novartis Ag | compositions comprising benzo (g) -quinoline derivatives and prostaglandin derivatives |
| JP2004307491A (en) * | 2004-03-24 | 2004-11-04 | Taisho Pharm Ind Ltd | Skin care preparation for external use containing heparinoid |
-
2006
- 2006-08-02 JP JP2006210644A patent/JP5252787B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007063265A (en) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5593345B2 (en) | Method for inhibiting degradation of isopropyl unoprostone | |
| JP5171606B2 (en) | Clear ophthalmic solution containing latanoprost as an active ingredient | |
| JP4762718B2 (en) | Prostaglandin-containing pharmaceutical composition | |
| JP2005002123A5 (en) | ||
| JP5661456B2 (en) | Eye drops and methods of use | |
| KR20160060656A (en) | Polyethylene glycol-containing composition | |
| EP1532981B1 (en) | Stable eye drops containing latanoprost as the active ingredient | |
| JP5252787B2 (en) | Method for inhibiting degradation of thermally unstable drugs | |
| JP2005263792A (en) | Clear latanoprost eye lotion | |
| JP7062846B1 (en) | Stable pharmaceutical composition | |
| JP4314429B2 (en) | Stable ophthalmic solution containing latanoprost as an active ingredient | |
| JP5253775B2 (en) | Latanoprost eye drops | |
| JP5420877B2 (en) | Ophthalmic agent | |
| JP2004123729A (en) | Clear eye lotion containing latanoprost as effective ingredient | |
| JP2007016024A (en) | Roflumilast eye drop | |
| JP2009256281A (en) | Isopropyl unoprostone containing ophthalmic preparation formulation | |
| TW201836611A (en) | Depot preparation comprising tafluprost and citric acid ester | |
| JP2010275259A (en) | Uniform and stable latanoprost ophthalmic liquid composition | |
| JP2019210288A (en) | Liquid chemical | |
| JP2009084262A (en) | Water-based medicine composition containing levocabastine and glycyrrhizic acid | |
| JP2010132572A (en) | Ophthalmic agent | |
| WO2005079809A1 (en) | Transparent latanoprost eye drops |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090115 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20090806 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090908 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100521 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101227 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110126 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110603 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130416 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5252787 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |